Venlafaxine in treatment-resistant obsessive-compulsive disorder

Eric Hollander, Jennifer Friedberg, Stacey Wasserman, Andrea Allen, Melissa Birnbaum, Lorrin M. Koran

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: While selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), approximately 40% of patients fail to respond to SSRIs. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that might be effective in the treatment of OCD, even among those who have failed previous SSRI trials. Method: Thirty-nine patients who met DSM-IV criteria for OCD, including 29 who were resistant to prior SRI treatment trials, were treated with venlafaxine in an open, naturalistic fashion. Improvement was assessed using the Clinical Global Impressions-Improvement scale. Results: Of 39 patients treated with venlafaxine, 27 (69.2%) were rated as sustained treatment responders. Of the 29 patients who did not respond to 1 or more previous SRI trials, 22 (75.9%) were rated as having sustained response to treatment. Mean dose of venlafaxine was 232.2 mg/day (range, 37.5-375 mg/day), and it was generally well tolerated. Conclusion: Venlafaxine may be beneficial to individuals with OCD, including those who have not responded to prior SSRI trials. However, these findings must be interpreted with caution, as the study is limited by its open, retrospective nature and its inclusion of patients with comorbid diagnoses and patients on concomitant medications. Prospective, controlled trials with a more homogeneous patient population are needed to replicate these preliminary findings.

Original languageEnglish (US)
Pages (from-to)546-550
Number of pages5
JournalJournal of Clinical Psychiatry
Volume64
Issue number5
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Therapeutics
Venlafaxine Hydrochloride
Diagnostic and Statistical Manual of Mental Disorders
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Hollander, E., Friedberg, J., Wasserman, S., Allen, A., Birnbaum, M., & Koran, L. M. (2003). Venlafaxine in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry, 64(5), 546-550.

Venlafaxine in treatment-resistant obsessive-compulsive disorder. / Hollander, Eric; Friedberg, Jennifer; Wasserman, Stacey; Allen, Andrea; Birnbaum, Melissa; Koran, Lorrin M.

In: Journal of Clinical Psychiatry, Vol. 64, No. 5, 01.05.2003, p. 546-550.

Research output: Contribution to journalArticle

Hollander, E, Friedberg, J, Wasserman, S, Allen, A, Birnbaum, M & Koran, LM 2003, 'Venlafaxine in treatment-resistant obsessive-compulsive disorder', Journal of Clinical Psychiatry, vol. 64, no. 5, pp. 546-550.
Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2003 May 1;64(5):546-550.
Hollander, Eric ; Friedberg, Jennifer ; Wasserman, Stacey ; Allen, Andrea ; Birnbaum, Melissa ; Koran, Lorrin M. / Venlafaxine in treatment-resistant obsessive-compulsive disorder. In: Journal of Clinical Psychiatry. 2003 ; Vol. 64, No. 5. pp. 546-550.
@article{489dbf9880364da9b71a6cad12a9d65a,
title = "Venlafaxine in treatment-resistant obsessive-compulsive disorder",
abstract = "Background: While selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), approximately 40{\%} of patients fail to respond to SSRIs. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that might be effective in the treatment of OCD, even among those who have failed previous SSRI trials. Method: Thirty-nine patients who met DSM-IV criteria for OCD, including 29 who were resistant to prior SRI treatment trials, were treated with venlafaxine in an open, naturalistic fashion. Improvement was assessed using the Clinical Global Impressions-Improvement scale. Results: Of 39 patients treated with venlafaxine, 27 (69.2{\%}) were rated as sustained treatment responders. Of the 29 patients who did not respond to 1 or more previous SRI trials, 22 (75.9{\%}) were rated as having sustained response to treatment. Mean dose of venlafaxine was 232.2 mg/day (range, 37.5-375 mg/day), and it was generally well tolerated. Conclusion: Venlafaxine may be beneficial to individuals with OCD, including those who have not responded to prior SSRI trials. However, these findings must be interpreted with caution, as the study is limited by its open, retrospective nature and its inclusion of patients with comorbid diagnoses and patients on concomitant medications. Prospective, controlled trials with a more homogeneous patient population are needed to replicate these preliminary findings.",
author = "Eric Hollander and Jennifer Friedberg and Stacey Wasserman and Andrea Allen and Melissa Birnbaum and Koran, {Lorrin M.}",
year = "2003",
month = "5",
day = "1",
language = "English (US)",
volume = "64",
pages = "546--550",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Venlafaxine in treatment-resistant obsessive-compulsive disorder

AU - Hollander, Eric

AU - Friedberg, Jennifer

AU - Wasserman, Stacey

AU - Allen, Andrea

AU - Birnbaum, Melissa

AU - Koran, Lorrin M.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: While selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), approximately 40% of patients fail to respond to SSRIs. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that might be effective in the treatment of OCD, even among those who have failed previous SSRI trials. Method: Thirty-nine patients who met DSM-IV criteria for OCD, including 29 who were resistant to prior SRI treatment trials, were treated with venlafaxine in an open, naturalistic fashion. Improvement was assessed using the Clinical Global Impressions-Improvement scale. Results: Of 39 patients treated with venlafaxine, 27 (69.2%) were rated as sustained treatment responders. Of the 29 patients who did not respond to 1 or more previous SRI trials, 22 (75.9%) were rated as having sustained response to treatment. Mean dose of venlafaxine was 232.2 mg/day (range, 37.5-375 mg/day), and it was generally well tolerated. Conclusion: Venlafaxine may be beneficial to individuals with OCD, including those who have not responded to prior SSRI trials. However, these findings must be interpreted with caution, as the study is limited by its open, retrospective nature and its inclusion of patients with comorbid diagnoses and patients on concomitant medications. Prospective, controlled trials with a more homogeneous patient population are needed to replicate these preliminary findings.

AB - Background: While selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), approximately 40% of patients fail to respond to SSRIs. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that might be effective in the treatment of OCD, even among those who have failed previous SSRI trials. Method: Thirty-nine patients who met DSM-IV criteria for OCD, including 29 who were resistant to prior SRI treatment trials, were treated with venlafaxine in an open, naturalistic fashion. Improvement was assessed using the Clinical Global Impressions-Improvement scale. Results: Of 39 patients treated with venlafaxine, 27 (69.2%) were rated as sustained treatment responders. Of the 29 patients who did not respond to 1 or more previous SRI trials, 22 (75.9%) were rated as having sustained response to treatment. Mean dose of venlafaxine was 232.2 mg/day (range, 37.5-375 mg/day), and it was generally well tolerated. Conclusion: Venlafaxine may be beneficial to individuals with OCD, including those who have not responded to prior SSRI trials. However, these findings must be interpreted with caution, as the study is limited by its open, retrospective nature and its inclusion of patients with comorbid diagnoses and patients on concomitant medications. Prospective, controlled trials with a more homogeneous patient population are needed to replicate these preliminary findings.

UR - http://www.scopus.com/inward/record.url?scp=0038475679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038475679&partnerID=8YFLogxK

M3 - Article

C2 - 12755657

AN - SCOPUS:0038475679

VL - 64

SP - 546

EP - 550

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -